Vertex boosts cell and genetic therapies toolkit in deal worth up to $1.2bn with Arbor

Vertex boosts cell and genetic therapies toolkit in deal worth up to $1.2bn with Arbor

Submitted by admin on August 30, 2021 - 10:57am
Source: 
Biopharma Reporter
News Tags: 
Vertex
cell therapy
gene therapy
CRISPR
gene editing
Arbor Biotechnologies
Headline: 
Vertex boosts cell and genetic therapies toolkit in deal worth up to $1.2bn with Arbor
snippet: 

Boston-based company, Vertex, has signed a deal to use Arbor Biotechnologies’ CRISPR gene-editing technology to develop novel cell therapies for the treatment of serious diseases.

Do Not Allow Advertisers to Use My Personal information